Krystal Biotech Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the company's redosable immunotherapy for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). The RMAT designation was granted based on early clinical evidence from the ongoing KYANITE-1 study, which showed consistent antitumor activity and clinically significant tumor reductions in patients with advanced NSCLC treated with inhaled KB707. The RMAT designation is intended to expedite the development and review of regenerative medicine therapies for serious or life-threatening conditions and provides benefits such as intensive FDA guidance and the potential for accelerated approval pathways. No other beneficiary organizations were mentioned in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9650490) on February 09, 2026, and is solely responsible for the information contained therein.